SEHK:1672Biotechs
Ascletis Pharma (SEHK:1672) Is Up 5.5% After Revealing Promising Obesity Drug Updates at ObesityWeek 2025 Has The Bull Case Changed?
Ascletis Pharma announced positive Phase Ib results for its ASC30 oral and subcutaneous formulations, showing notable placebo-adjusted mean body weight reduction, a favorable safety profile, and ultra-long half-lives supporting both monthly and quarterly dosing, with these updates presented recently at ObesityWeek 2025.
The company also unveiled new preclinical results where a combination of ASC47 and ASC31 outperformed monotherapies in promoting both weight and fat loss, and advanced its...